Literature DB >> 17981144

Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican.

Marie-France D'Onofrio1, Stéphane Brézillon, Thomas Baranek, Corinne Perreau, Peter J Roughley, François-Xavier Maquart, Yanusz Wegrowski.   

Abstract

Lumican is a small leucine-rich proteoglycan (SLRP) present in the dermal extracellular matrix. Previous data from our laboratory demonstrated that lumican decreases melanoma progression in vivo. Here, we show that melanoma cell migration is decreased by lumican and that this effect is due to an enhanced cell adhesion. The adhesion of A375 human melanoma cells on lumican was dose-dependent and required Mg2+ and Mn2+ divalent cations. Using a panel of monoclonal antibodies directed against integrin subunits, we showed that A375 cells can bind to recombinant lumican through beta1 type integrins. Moreover, the use of rhodocetin, an inhibitor of alpha2 integrin, suggested that this particular subunit might also be involved in the interaction with lumican. The increased beta1 integrin-mediated adhesion of melanoma cells to lumican might explain, at least in part, the anti-invasive effect of this SLRP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981144     DOI: 10.1016/j.bbrc.2007.10.155

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 2.  Proteoglycans in prostate cancer.

Authors:  Iris J Edwards
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

Review 3.  Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.

Authors:  Renato V Iozzo; Liliana Schaefer
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

4.  Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis.

Authors:  Kent E Williams; Logan A Fulford; Allan R Albig
Journal:  Cancer Microenviron       Date:  2010-11-18

Review 5.  The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly.

Authors:  Shoujun Chen; David E Birk
Journal:  FEBS J       Date:  2013-02-14       Impact factor: 5.542

6.  Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin.

Authors:  Seakwoo Lee; Kyle Bowrin; Abdel Rahim Hamad; Shukti Chakravarti
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

7.  Lumican expression, localization and antitumor activity in prostate cancer.

Authors:  Vivien J Coulson-Thomas; Yvette M Coulson-Thomas; Tarsis F Gesteira; Claudia A Andrade de Paula; Celia R W Carneiro; Valdemar Ortiz; Leny Toma; Winston W-Y Kao; Helena B Nader
Journal:  Exp Cell Res       Date:  2013-02-08       Impact factor: 3.905

8.  Lumican negatively controls the pathogenicity of murine encephalitic TH17 cells.

Authors:  Eliseo F Castillo; Handong Zheng; Christian Van Cabanlong; Fei Dong; Yan Luo; Yi Yang; Meilian Liu; Winston W-Y Kao; Xuexian O Yang
Journal:  Eur J Immunol       Date:  2016-10-24       Impact factor: 5.532

9.  Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity.

Authors:  Jin-Young Lee; Da-Ae Kim; Eun-Young Kim; Eun-Ju Chang; So-Jeong Park; Beom-Jun Kim
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 10.  Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.

Authors:  Renato V Iozzo; Ralph D Sanderson
Journal:  J Cell Mol Med       Date:  2011-05       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.